| Acquired by | Bayer HealthCare |
| Price | $297M |
| Date | 9/08 |
| Website | direvo.com |
| Category | BioTech |
| Phone | +49 221-47448-0 |
| info@direvo.com | |
| Employees | |
| Founded | 2000 |
| TOTAL | $33.2M |
| VENTURE FUNDING TOTAL | $33.2M |
| Series C, 10/07 Bankhaus Wölbern TVM Capital NRW.BANK Danisco Venture S-Equity Partner Mulligan BioCapital Signet Healthcare Partners | $16.8M |
| Venture Round, 2/10 TVM Capital NRW.BANK | €6M |
| Series D, 4/10 TVM Capital NRW.BANK | $8.1M |
DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.
